Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07ZNF
|
||||
| Former ID |
DND000013
|
||||
| Drug Name |
IMC-EB10
|
||||
| Synonyms |
Anti-Flt-3 Mab
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] | Phase 1 | [522646] | ||
| Company |
Eli Lilly
|
||||
| Target and Pathway | |||||
| Target(s) | FL cytokine receptor | Target Info | [528177], [530685] | ||
| References | |||||
| Ref 528177 | IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51. | ||||
| Ref 530685 | Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. Cancer. 2010 Feb 15;116(4 Suppl):1013-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.